1614

Docket No. ORT-1581

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Carlos R. Plata-Salaman et al.

Serial No. : 10/081,606

Art Unit: 1614

Filed

: February 21, 2002

Examiner: Donna A. Jagoe

For

: Carbamate Compounds for use in Preventing or

Treating Bipolar Disorders

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

March 8, 2006
(Date of Deposit)

Peter L. Herridge (Name of applicant, assignee, or Registered Representative)

/Peter L Herridge/
(Signature)

March 8, 2006

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on January 5, 2006.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the

information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information

X

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with | the first or second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or \Box Please charge Deposit Account No. 10the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an

action that otherwise closes prosecution and that it is
accompanied by one of:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).
<u></u>
\square In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
™
Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a) (2).
There are no listed references which are not in the
English language.
English language.
The relevance of those listed references which are
not in the English language is as follows:
not in the English language is as lollows.
Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Copies of the references listed on the search
report(s) are included except for those previously cited in an
IDS mailed

r.,

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1581/PLH. This form is submitted in triplicate.

Respectfully submitted,

_/Peter L Herridge/ Peter L. Herridge Reg. No. 42,658 Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-5352
DATED: March 8, 2006

MAR 0 9 2006

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE syction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute to form 1449A/PTQ

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

a competition and another and contraction of	Tano Onio Control Hamber.
Application Number	10/081,606
Filing Date	February 21, 2002
First Named Inventor	C. R. Plata-Salaman
Group Art Unit	1614
Examiner Name	D. A. Jagoe
Attorney Docket Number	ORT-1581

U.S. PATENT DOCUMENTS						
		U.S. Patent Do	ocument			
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages relevant figures appear
		-		· · · · · ·		
	ļ					
			1101 18			
		<u> </u>	FORFIC	ON PATENT DOCUMENTS	<u> </u>	L

				FURE	IGN PATENT DOCUMENTS			
		Foreign	Patent Doci	ument	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No.1	Office ³	Number ⁴	KindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
					24.			
								3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
		POST ET AL., "A History of the Use of Anticonvulsants as Mood Stabilizers in the Last Two Decades of the 20 th Century", Neuropsychobiology (1988), Vol. 38, pp 152-166.			

Examiner	Date
Signature	Considered
Olgridiate	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.